Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Melanoma 105Skin Neoplasms 17Neoplasm Metastasis 15Neoplasms 10Uveal Melanoma 9Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Kidney Neoplasms 6Colorectal Neoplasms 6Carcinoma, Merkel Cell 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Lung Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Lymphoma 2Eye Neoplasms 2Carcinoma, Hepatocellular 2Urogenital Neoplasms 1Turcot syndrome 1Sezary Syndrome 1Sarcoma, Synovial 1

Interventions

pembrolizumab 14Nivolumab 10atezolizumab 5durvalumab 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4avelumab 3Specimen Handling 3Radiosurgery 3Magnetic Resonance Spectroscopy 3temsirolimus 2poly ICLC 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2budigalimab 2aldesleukin 2abiraterone 2Radiotherapy 2Interleukin-2 2Gemcitabine 2venetoclax 1utomilumab 1trastuzumab deruxtecan 1tislelizumab 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Interleukin-2 × Dermatologic × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

Phase 1 Terminated
49 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡